A Study of the Pharmacokinetics And Pharmacodynamics of Intravenously Administered Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C And Previous Non-Response to Pegylated Interferon And Ribavirin Combination Therapy

Inclusion Criteria: * Adult caucasian patients, 18 - 70 years of age * Hepatitis C, genotype 1 * Non-responder to previous anti-HCV therapy with peginterferon alfa and ribavirin * Compensated liver disease (Child-Pugh class A) for \>/= 24 months before baseline * Positive for anti-HCV for \> 6 months, with detectable serum HCV-RNA Exclusion Criteria: * Treatment-naïve or responder to previous therapy * HCV infection other than genotype 1 * Positive for Hepatitis A, Hepatitis B or HIV infection at screening * Chronic Hepatitis of other than HCV origin * Decompensated liver disease (Child-Pugh class B or C) * Therapy with systemic antiviral, antineoplastic or immunomodulatory agents in the 6 months prior to study * Clinically relevant retina disorder * Pregnant or lactating women and male partners of pregnant women